Media coverage about Dipexium Pharmaceuticals (NASDAQ:PLXP) has trended positive on Saturday, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Dipexium Pharmaceuticals earned a daily sentiment score of 0.46 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 46.4719847160472 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
Shares of Dipexium Pharmaceuticals (NASDAQ PLXP) remained flat at $6.90 during trading on Friday. The stock had a trading volume of 6,656 shares. Dipexium Pharmaceuticals has a 1-year low of $5.60 and a 1-year high of $142.01. The company has a 50 day moving average price of $6.30 and a 200-day moving average price of $7.99. The firm’s market capitalization is $59.95 million.
Several analysts recently weighed in on PLXP shares. Redburn Partners raised Dipexium Pharmaceuticals to an “outperform” rating in a research note on Tuesday, August 1st. UBS AG upgraded Dipexium Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $12.00 target price for the company in a research report on Monday, July 31st. Finally, Zacks Investment Research downgraded Dipexium Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday. Two investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $7.00.
ILLEGAL ACTIVITY NOTICE: “Dipexium Pharmaceuticals (NASDAQ:PLXP) Earning Positive Media Coverage, Accern Reports” was originally published by BNB Daily and is the property of of BNB Daily. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://www.baseball-news-blog.com/2017/08/19/positive-news-coverage-somewhat-unlikely-to-affect-dipexium-pharmaceuticals-nasdaqplxp-stock-price-updated.html.
In other Dipexium Pharmaceuticals news, insider Michael J. Valentino purchased 29,091 shares of Dipexium Pharmaceuticals stock in a transaction dated Wednesday, June 14th. The shares were acquired at an average cost of $6.88 per share, with a total value of $200,146.08. Following the completion of the transaction, the insider now owns 122,386 shares in the company, valued at approximately $842,015.68. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CFO David Emerson Jorden purchased 32,727 shares of Dipexium Pharmaceuticals stock in a transaction dated Wednesday, June 14th. The shares were acquired at an average cost of $6.88 per share, for a total transaction of $225,161.76. Following the completion of the transaction, the chief financial officer now owns 151,913 shares of the company’s stock, valued at approximately $1,045,161.44. The disclosure for this purchase can be found here. Insiders purchased 69,091 shares of company stock valued at $475,346 in the last three months. 47.70% of the stock is currently owned by insiders.
Dipexium Pharmaceuticals Company Profile
PLx Pharma Inc, formerly Dipexium Pharmaceuticals, Inc, is a biopharmaceutical company. The Company is a late stage specialty pharmaceutical company focusing on commercializing its lead products: Aspertec 325 mg and Aspertec 81 mg (Aspertec). The Company’s products and technology includes PLxGuard delivery system, Aspertec 325 mg, PL1100/PL1200 Ibuprofen.
Receive News & Ratings for Dipexium Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dipexium Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.